Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.

  title={Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.},
  author={Markus Weiler and Christian Hartmann and Dorothee Wiewrodt and Ulrich Herrlinger and Thierry Gorlia and Oliver B{\"a}hr and Richard Meyermann and Michael Bamberg and Marcos Tatagiba and Andreas von Deimling and Michael Weller and Wolfgang Wick},
  journal={International journal of radiation oncology, biology, physics},
  volume={77 3},
PURPOSE To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. PATIENTS AND METHODS A total of 41 adult patients (median Karnofsky performance status, 90%; median age, 56 years) were treated with preirradiation TMZ at 150 mg/m(2) (1 week on/1 week off), involved-field radiotherapy combined with concomitant low-dose TMZ (50 mg/m(2… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 27 extracted citations


Publications referenced by this paper.
Showing 1-10 of 24 references

A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo)astrocytoma: An interim analysis of toxicity [Abstract

  • B Neyns, B van Mierlo, J Menten
  • J Clin Oncol 2005;23
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…